20:30:36 Europe / Stockholm

Prenumeration

2024-07-02 08:21:00

Redeye provides an update as we resume our coverage after CLS’ rights issue. We adjust our model accordingly to the rights issue outcome, make estimate changes following the company’s increased focus on neurosurgery, and comment on CLS’ Q1 report. As a result, we provide an updated diluted fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/